Cancro al seno HER2+ metastatico, trastuzumab deruxtecan riduce di oltre un terzo rischio di morte
The San Antonio Breast Cancer Symposium (SABCS), the premier conference for breast cancer oncologists, has delivered important news regarding the treatment of advanced-stage HER2-positive breast cancer, meaning it overexpresses the HER2 receptor. New data from the DESTINY-Breast-03 study were presented at the symposium, consolidating the role of a new agent, the antibody-drug conjugate (ADC) trastuzumab deruxtecan, in the treatment of these patients. We discuss this in this interview with breast cancer expert Dr. Giampaolo Bianchini, Head of the Breast Unit in the Department of Oncology at IRCCS San Raffaele Hospital in Milan.
▶︎
Tumore al seno HER2+ metastatico, con trastuzumab deruxtecan rischio di progressione ridotto del 72%
▶︎
Trastuzumab deruxtecan: confirmation from San Antonio
▶︎
HER2-positive breast cancer: New treatment effective against brain metastases
▶︎
Tumore al polmone: perché alcuni tumori resistono all’immunoterapia?
▶︎
Cancro al seno ER+/HER2- metastatico, con elacestrant si allontana la progressione
▶︎
Before you Start or Refuse Cancer Therapy- WATCH THIS!
▶︎
ASCO 2024: Innovazioni in Oncologia e novità Trattamento del Cancro al Seno e al Polmone
▶︎
Carcinoma mammario metastatico HER2+, trastuzumab deruxtecan triplica la sopravvivenza
▶︎
Chemioterapia - Effetti Collaterali: Come Prevenirli e Combatterli
▶︎
Tumore al seno Her 2 +, nuove opzioni terapeutiche per le fasi precoci per prevenire recidive
▶︎
Use These 5 Food Hacks To Heal The Body & STARVE CANCER I Dr. William Li
▶︎
Clinical Cases #80 - Efficacia di trastuzumab deruxtecan nella malattia avanzata HER2+
▶︎
Tumore al seno metastatico, uno studio cambia la cura
▶︎
Rivoluzione nel trattamento del tumore al seno metastatico: approvato trastuzumab deruxtecan
▶︎
Chemo Port: Things You Want to Know… But Didn’t Ask
▶︎
HER2-low and HER2-ultralow breast cancer
▶︎
Tumore al Seno Metastatico: il racconto di chi lo combatte ogni giorno
▶︎
Tumore al seno HER2+, come ridurre al massimo il rischio residuo di recidiva?
▶︎
Breast Cancer: Classification, Staging, and How to Read a Report
▶︎